- Bone Biologics Corporation (BBLG, Financial) files a patent application for its innovative NELL-1 protein.
- The application aims to enhance the company's intellectual property in bone regeneration technologies.
- The advancement underlines Bone Biologics' commitment to spine fusion solutions.
BURLINGTON, Mass.--Bone Biologics Corporation (NASDAQ:BBLG, BBLGW), a leading developer of orthobiologic products for spine fusion markets, has announced the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein. This patent application, if approved, will focus on compositions of rhNELL-1 polypeptide and its uses in treating bone conditions.
According to Jeffrey Frelick, Chief Executive Officer of Bone Biologics, this patent application is a significant milestone in the company's mission to provide effective treatments for spine fusion patients. The filing is set to bolster Bone Biologics’ intellectual property portfolio and align with the company’s strategy to further its clinical development program.
Bone Biologics is dedicated to pioneering regenerative medicine for bone, concentrating primarily on bone regeneration in spinal fusion procedures. The ongoing development of its bone graft substitute product also extends to potential applications in trauma and osteoporosis. This latest patent application represents a critical step towards improving bone regeneration solutions and expanding Bone Biologics' presence in the global market.
